Get 40% Off
🔥 This hedge fund gained 26.16% in the last month. Get their top stocks with our free stock ideas tool.See stock ideas

Bristol-Myers Opdivo Positive In Phase II Study CheckMate-205

Published 06/18/2017, 10:52 PM
Updated 07/09/2023, 06:31 AM
MRK
-
BMY
-
SGEN
-
VVUSQ
-

Bristol-Myers Squibb Company (NYSE:BMY) announced an extended follow-up data on immuno-oncology drug Opdivo.

The data from ongoing phase II study CheckMate-205 evaluated adult patients with classical Hodgkin lymphoma (cHL) who have failed autologous stem cell transplant (ASCT), irrespective of brentuximab vedotin (BV) therapy history.

The study evaluated objective response rates (ORR), the primary endpoint, as well as duration of response rates (DOR) for each cohort (assessed by the Independent Radiology Review Committee).

The data from the study showed that Opdivo demonstrated responses in adult patients with relapsed or progressed cHL after ASCT, irrespective of BV therapy history.

The patients had an ORR of 65%, with a complete response (CR) in 29% of patients, in the BV-naïve group (Cohort A: n=63). They had a median follow-up of 19 months. The median DOR was 20 months and the median progression-free survival (PFS) was 18.3 months.

The ORR was 68% in next group that had BV therapy after ASCT (Cohort B: n=80), with a median follow-up of 23 months. The CR was 13% in this cohort. The median DOR was 16 months and the median PFS was 14.7 months.Across cohorts, the median overall survival was not reached, and 40% of patients remained on treatment. The safety profile was consistent with the previously reported data in this tumor type.

We note that Opdivo became the first PD-1 inhibitor to be approved for a hematological malignancy – classic Hodgkin lymphoma in both the U.S. (May 2016) and the EU (Nov 2016).

The indication received accelerated approval based on overall response rate. The continued approval for this indication is contingent upon verification and description of clinical benefit in confirmatory trials.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

In Nov 2016, Opdivo gained the FDA approval for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after platinum-based therapy.

Label expansion into additional indications would give the product access to a higher patient population and increase the commercial potential of the drug.

However, the company suffered a setback in Jan 2017 when it decided not to pursue accelerated regulatory pathway for Opdivo plus Yervoy in first-line lung cancer in the U.S. based on a review of available data. The share price of the company declined significantly on the news.

While Bristol-Myers’ shares declined 6.8% in the last 12 months, the Zacks classified Large Cap Pharmaceuticals industry gained 11.4%.

Moreover, Opdivo is facing stiff competition in the U.S. With the FDA approving Merck’s (NYSE:MRK) Keytruda, for the first-line treatment of metastatic nonsquamous NSCLC, the company is expected to suffer further loss of market share.

Bristol-Myers has entered into a collaboration agreement with Seattle Genetics, Inc. (NASDAQ:SGEN) to evaluate the combination of Opdivo and Seattle Genetics’ antibody drug conjugate (ADC) Adcetris in a phase III trial as a potential treatment option for patients with relapsed/refractory or transplant-ineligible advanced cHL.

Zacks Rank & Key Pick

Bristol-Myers currently carries a Zacks Rank #3 (Hold).

A better-ranked stock in the health care sector is VIVUS, Inc. (NASDAQ:VVUS) which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

VIVUS’ loss per share estimates have narrowed from 50 cents to 39 cents for 2017 in the last 60 days. The company delivered positive earnings surprises in the four trailing quarters, with an average beat of 233.69%.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>





Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report

Merck & Company, Inc. (MRK): Free Stock Analysis Report

VIVUS, Inc. (VVUS): Free Stock Analysis Report

Seattle Genetics, Inc. (SGEN): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.